In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: Failure in IL-2 production despite proliferation

Human Immunology

Volumn 60, Issue 3, 1999, Pages 187-199

  Eckels, David D ^a   Tabatabail, Niloofar ^a   Bian, Tong Hua ^a   Wang, Huiru ^a   Muheisen, Sanaa S ^a   Rice, Charles M ^b   Yoshizawa, Kaname ^c   Gill, Joan ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokines; HCV; Immunoregulation; T cells; Viral immunology

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; HEPATITIS C ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HELPER CELL; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REGULATORY MECHANISM; VIRUS LOAD;

HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; RECOMBINANT PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0032904882     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(98)00111-6     Document Type: Article

References (50)

1. Alter H.J. To C or not to C these are the questions . Blood. 85:1995;1681-1695. [Review].
2. Koziel M.J., Dudley D., Wong J.T., Dienstag J., Houghton M., Ralston R., Walker B.D. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol. 149:1992;3339-3344.
3. Koziel M.J., Wong D.K., Dudley D., Houghton M., Walker B.D. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis. 176:1997;859-866.
4. Cerny A., McHutchison J.G., Pasquinelli C., Brown M.E., Brothers M.A., Grabscheid B., Fowler P., Houghton M., Chisari F.V. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2 1 binding motif . J Clin Invest. 95:1995;521-530.
5. Chang K.M., Rehermann B., McHutchison J.G., Pasquinelli C., Southwood S., Sette A., Chisari F.V. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest. 100:1997;2376-2385.
6. Botarelli P., Brunetto M.R., Minutello M.A., Calvo P., Unutmaz D., Weiner A.J., Choo Q.L., Shuster J.R., Kuo G., Bonino F., Houghton M., Abrignani S. T-lymphocyte responses to hepatitis C virus in different courses of infection. Gastroenterol. 104:1993;580-587.
7. Minutello M.A., Pileri P., Unutmaz D., Censini S., Kuo G., Houghton M., Brunetto M.R., Bonino F., Abrignani S. Compartmentalization of T lymphocytes to the site of disease Intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C . J Exp Med. 178:1993;17-25.
8. Eckels D.D., Flomenberg P., Gill J.C. Hepatitis C virus models of immunopathogenesis and prophylaxis . Transfusion. 36:1996;836-844.
9. Reiser M., Marousis C.G., Nelson D.R., Lauer G., González-Peralta R.P., Davis G.L., Lau J.Y. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol. 26:1997;471-478.
10. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection implications for hepatitis C virus chronicity . Hepatology. 25:1997;449-458.
11. Bertoletti A., Sette A., Chisari F.V., Penna A., Levrero M., De Carli M., Fiaccadori F., Ferrari C. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature. 369:1994;407-410.
12. Napoli J., Bishop G.A., McGuinness P.H., Painter D.M., McCaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology. 24:1996;759-765.
13. Laskus T., Radkowski M., Wang L.F., Vargas H., Rakela J. Lack of evidence for hepatitis G virus replication in the livers of patients coinfected with hepatitis C and G viruses. J Virol. 71:1997;7804-7806.
14. Shimizu Y.K., Iwamoto A., Hijikata M., Purcell R.H., Yoshikura H. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci USA. 89:1992;5477-5481.
15. Zignego A.L., Macchia D., Monti M., Thiers V., Mazzetti M., Foschi M., Maggi E., Romagnani S., Gentilini P., Brechot C. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol. 15:1992;382-386.
16. Bouffard P., Hayashi P.H., Acevedo R., Levy N., Zeldis J.B. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis. 166:1992;1276-1280.
17. Ikeda M., Kato N., Mizutani T., Sugiyama K., Tanaka K., Shimotohno K. Analysis of the cell tropism of HCV by using in vitro HCV-infected human lymphocytes and hepatocytes. J Hepatol. 27:1997;445-454.
18. Martell M., Esteban J.I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes quasispecies nature of HCV genome distribution . J Virol. 66:1992;3225-3229.
19. De Lamballerie X., Charrel R.N., Attoui H., De Micco P. Classification of hepatitis C virus variants in six major types based on analysis of the envelope 1 and nonstructural 5B genome regions and complete polyprotein sequences. J Gen Virol. 78:1997;45-51.
20. Weiner A.J., Geysen H.M., Christopherson C., Hall J.E., Mason T.J., Saracco G., Bonino F., Crawford K., Marion C.D., Crawford K.A., et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants potential role in chronic HCV infections . Proc Natl Acad Sci USA. 89:1992;3468-3472.
21. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., Mushahwar I.K., Desai S.M., Miller R.H., Ogata N., Purcell R.H. Lack of protective immunity against reinfection with hepatitis C virus. Science. 258:1992;135-140.
22. Farci P., London W.T., Wong D.C., Dawson G.J., Vallari D.S., Engle R., Purcell R.H. The natural history of infection with hepatitis C virus (HCV) in chimpanzees comparison of serologic responses measured with first- and second-generation assays and relationship to HCV viremia . J Infect Dis. 165:1992;1006-1011.
23. Klenerman P., Rowland-Jones S., McAdam S., Edwards J., Daenke S., Lalloo D., Koppe B., Rosenberg W., Boyd D., Edwards A., et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature. 369:1994;403-407.
24. Meier UC, Klenerman P, Griffin P, James W, Koppe B, Larder B, McMichael A, Phillips R: Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science 270:1360-1362, 11-24-1995.
25. Woitas R.P., Lechmann M., Jung G., Kaiser R., Sauerbruch T., Spengler U. CD30 induction and cytokine profiles in Hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol. 159:1997;1012-1018.
26. Yoshioka K., Kakumu S., Wakita T., Ishikawa T., Itoh Y., Takayanagi M., Higashi Y., Shibata M., Morishima T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy relationship to genotypes of hepatitis C virus . Hepatology. 16:1992;293-299.
27. Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., Rice C.M. Characterization of the hepatitis C virus-encoded serine proteinase Determination of proteinase-dependent polyprotein cleavage sites . J Virol. 67:1993;2832-2843.
28. Grakoui A., Wychowski C., Lin C., Feinstone S.M., Rice C.M. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 67:1993;1385-1395.
29. Kim J.L., Morgenstern K.A., Lin C., Fox T., Dwyer M.D., Landro J.A., Chambers S.P., Markland W., Lepre C.A., O'Malley E.T., Harbeson S.L., Rice C.M., Murcko M.A., Caron P.R., Thomson J.A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 87:1996;343-355.
30. Colligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W. Current Protocols in Immunology. 1994;John Wiley & Sons, Inc, New York.
31. Kledal T., Rosenkilde M., Coulin F., Simmons G., Johnsen A., Alouani S., Power C., Lüttichau H., Gerstoft J., Clapham P., Clark-Lewis I., Wells T., Schwartz T. A broad-spectrum chemokine antagonist encoded by Kaposi's Sarcoma-associated herpesvirus. Science. 277:1997;1656-1659.
32. Gooding L.R., Wold W.S. Molecular mechanisms by which adenoviruses counteract antiviral immune defenses. Crit Rev Immunol. 10:1990;53-71.
33. Gooding L.R. Virus proteins that counteract host immune defenses. Cell. 71:1992;5-7.
34. Burdin N., Peronne C., Banchereau J., Rousset F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med. 177:1993;295-304.
35. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.-G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 174:1991;915-924.
36. Del Prete G., De Carli M., Almerigogna F., Giudizi M.G., Biagiotti R., Romagnani S. Human IL-10 is produced by both Type 1 helper (Th1) and Type 2 helper (Th2) cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 150:1993;353-360.
37. Ding L., Linsley P.S., Huang L.-Y., Germain R.N., Shevach E.M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol. 151:1993;1224-1234.
38. Schwartz R.H. Costimulation of T lymphocytes the role of CD28, CTLA- 4, and B7/BB1 in interleukin-2 production and immunotherapy . Cell. 71:1992;1065-1068.
39. Boussiotis V.A., Freeman G.J., Berezovskaya A., Barber D.L., Nadler L.M. Maintenance of human T cell anergy Blocking of IL-2 gene transcription by activated Rap1 . Science. 278:1997;124-128.
40. Sloan-Lancaster J., Evavold B.D., Allen P.M. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature. 363:1993;156-159.
41. Evavold B.D., Allen P.M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 252:1991;1308-1310.
42. Evavold B.D., Sloan-Lancaster J., Allen P.M. Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand. Proc Natl Acad Sci USA. 91:1994;2300-2304.
43. Legge K., Min B., Potter N.T., Zaghouani H. Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processing. J Exp Med. 185:1997;1043-1053.
44. Tabatabai N., Bian T.H., Rice C.M., Yoshizawa K., Gill J., Eckels D.D. Functionally distinct T-cell epitopes within the Hepatitis C Virus non-structural 3 protein. Hum Immunol. 60:1999;105-115.
45. Ballardini G., Groff P., Pontisso P., Giostra F., Francesconi R., Lenzi M., Zauli D., Alberti A., Bianchi F.B. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C . J Clin Invest. 95:1995;2067-2075.
46. Rice C.M., Walker C.M. Hepatitis C virus-specific T lymphocyte responses. Curr Op Immunol. 7:1995;532-538.
47. Geissler M., Gesien A., Tokushige K., Wands J.R. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 158:1997;1231-1237.
48. Zhang Z.X., Milich D.R., Peterson D.L., Birkett A., Schvarcz R., Weiland O., Sällberg M. Interferon-a treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J Infect Dis. 175:1997;1294-1301.
49. Pardo M., Castillo I., Oliva H., Fernández-Flores A., Bárcena R., De Peuter M.A., Carreño V. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology. 26:1997;1318-1321.
50. Moore K.W., O'Garra A., de Waal M.R., Vieira P., Mosmann T.R. Interleukin-10. Ann Rev Immunol. 11:1993;165-190.